Hepatocellular Carcinoma Recurrent Clinical Trial
Official title:
A RCT Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .
Background & Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world. The 5-year recurrent rate of HCC after first curative resection is 77%~100%. Laparoscopic repeat liver resection (LRLR) has been shown in small retrospective studies to be a safe and effective treatment for recurrent hepatocellular carcinoma (rHCC) in selected patients, and radiofrequency ablation (RFA) has been increasingly performed for treating recurrent tumors involving the liver after hepatectomy. The aim of this study was to compare the short-term and long-term outcome of laparoscopic hepatectomy (LH) and radiofrequency ablation (RFA) in the treatment of rHCC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04506398 -
Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence
|
||
| Recruiting |
NCT05417932 -
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05277675 -
Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
|
N/A | |
| Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05355155 -
Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
|
Phase 2 | |
| Recruiting |
NCT04392700 -
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection
|
Phase 3 | |
| Terminated |
NCT01009593 -
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Completed |
NCT02423343 -
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT06233708 -
Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
|
||
| Recruiting |
NCT04425226 -
Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant
|
N/A | |
| Recruiting |
NCT05497453 -
A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05990959 -
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
|